The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".

The drug is administered via injection and offers long-lasting efficacy, with a monthly maintenance dose required after the ...

Overview: Eli Lilly and Company discovers ... Recent FDA approval for new treatments like EBGLYSS and positive trial results bolster its financial outlook amidst executive changes and strategic ...

Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

INDIANAPOLIS–The U.S. Food and Drug Administration has approved Eli Lilly’s new treatment for moderate to severe eczema. It’s ...

The original concerns of the US regulatory agency over the manufacturing of Eli Lilly’s Ebglyss seem to have been resolved, ...

Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above ...

In the United States and some countries other than Europe, Lilly owns exclusive development and commercialization rights to ...

APPROVAL has been granted by the FDA for lebrikizumab-lbkz in treating moderate to severe atopic dermatitis (AD) in patients ...